{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:58:12Z","timestamp":1781297892072,"version":"3.54.1"},"reference-count":79,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,10,30]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>A common complication in systemic sclerosis (SSc) is the development of SSc-associated interstitial lung disease (SSc-ILD), which has poor prognosis and a high mortality rate. The pulmonary microenvironment may include mediators involved in disease pathogenesis that could be targets for new therapies to reduce SSc-to\u2013SSc-ILD transition. Here, we aimed to identify soluble mediators in bronchoalveolar lavage fluid that would differentiate patients with SSc-ILD from those with SSc only through a systematic review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a preregistered study protocol, 2 databases (Web of Science, PubMed) were screened for publications between 2000 and 2024 in adult patients (keywords \u201csystemic sclerosis AND biomarker AND [lung lavage OR bronchoalveolar lavage]\u201d). Mediators were metaanalyzed (RevMan) and functionally enriched pathways identified (STRING-DB\/G:Profiler).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Screening identified 20\/82 publications for inclusion into the systematic review, with qualitative syntheses (n = 12) and metaanalyses (n = 5). Thirty different mediators were identified, 17 were available for SSc vs SSc-ILD comparison. Mediators showed strong interconnectedness and were clustered into the following 3 groups: (1) those released from tertiary granules (predominately involved in remodeling of extracellular matrix), (2) those with chemokine receptor binding, and (3) those with antioxidant function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Due to the limited number of studies, we were unable to perform a metaanalysis on mediators between SSc and SSc-ILD, highlighting the need for further studies. However, our review strongly highlights the involvement of the pulmonary epithelium in SSc-ILD, contributing to positive feedback between injured epithelial cells and fibroblast activation\/fibrosis. Further research into the role of the epithelium is needed to identify novel mechanisms leading to SSc-ILD that could serve as novel pharmacological targets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0322","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T13:20:17Z","timestamp":1763212817000},"page":"592-602","source":"Crossref","is-referenced-by-count":0,"title":["The Role of the Pulmonary Microenvironment in Driving Transition From Systemic Sclerosis to Systemic Sclerosis\u2013Associated Interstitial Lung Disease"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8312-0873","authenticated-orcid":false,"given":"Rosa I.","family":"Rodr\u00edguez Viera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2692-5628","authenticated-orcid":false,"given":"Julia","family":"Malitska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0566-3919","authenticated-orcid":false,"given":"Susan","family":"Sultani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3325-6996","authenticated-orcid":false,"given":"Nazia","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-0940","authenticated-orcid":false,"given":"Guillermo","family":"Lopez-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0259-8515","authenticated-orcid":false,"given":"Koray N.","family":"Potel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7483-740X","authenticated-orcid":false,"given":"Steven","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1433-0188","authenticated-orcid":false,"given":"Bettina C.","family":"Schock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"key":"2026061213100666000_53.6.592.1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-0980-7"},{"key":"2026061213100666000_53.6.592.2","doi-asserted-by":"publisher","DOI":"10.5301\/jsrd.5000238"},{"key":"2026061213100666000_53.6.592.3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/1744666X.2023.2198212","article-title":"Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease","volume":"19","author":"Makol","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"2026061213100666000_53.6.592.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02026-2019"},{"key":"2026061213100666000_53.6.592.5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026061213100666000_53.6.592.6","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-017-0654-2"},{"key":"2026061213100666000_53.6.592.7","doi-asserted-by":"crossref","first-page":"102978","DOI":"10.1016\/j.autrev.2021.102978","article-title":"Pharmacological treatments for SSc-ILD: systematic review and critical appraisal of the evidence","volume":"20","author":"Vonk","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2026061213100666000_53.6.592.8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5301\/jsrd.5000220","article-title":"Updates on animal models of systemic sclerosis","volume":"1","author":"Soare","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"key":"2026061213100666000_53.6.592.9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/thorax-2022-219226","article-title":"Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses","volume":"78","author":"Fields","year":"2022","journal-title":"Thorax"},{"key":"2026061213100666000_53.6.592.10","doi-asserted-by":"publisher","DOI":"10.2174\/1874306400903010123"},{"key":"2026061213100666000_53.6.592.11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"key":"2026061213100666000_53.6.592.12","doi-asserted-by":"crossref","unstructured":"Borenstein M , Hedges LV , Higgins JPT , Rothstein HR , ed. Effect sizes based on means. In: Introduction to meta-analysis. Hoboken: John Wiley & Sons; 2009:21-32.","DOI":"10.1002\/9780470743386"},{"key":"2026061213100666000_53.6.592.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3472"},{"key":"2026061213100666000_53.6.592.14","doi-asserted-by":"publisher","DOI":"10.1093\/NAR\/GKAC1000"},{"key":"2026061213100666000_53.6.592.15","doi-asserted-by":"publisher","DOI":"10.1007\/s004080000058"},{"key":"2026061213100666000_53.6.592.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014019"},{"key":"2026061213100666000_53.6.592.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.022970"},{"key":"2026061213100666000_53.6.592.18","doi-asserted-by":"publisher","DOI":"10.1186\/ar2067"},{"key":"2026061213100666000_53.6.592.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2007.04.019"},{"key":"2026061213100666000_53.6.592.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.22559"},{"key":"2026061213100666000_53.6.592.21","doi-asserted-by":"publisher","DOI":"10.1186\/ar2766"},{"key":"2026061213100666000_53.6.592.22","first-page":"S71","article-title":"CXCL11 in bronchoalveolar lavage fluid and pulmonary function decline in systemic sclerosis","volume":"30","author":"Sfriso","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2026061213100666000_53.6.592.23","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-22"},{"key":"2026061213100666000_53.6.592.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.03.015"},{"key":"2026061213100666000_53.6.592.25","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-015-0308-1"},{"key":"2026061213100666000_53.6.592.26","doi-asserted-by":"publisher","DOI":"10.1177\/2040622320956420"},{"key":"2026061213100666000_53.6.592.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.10.009"},{"key":"2026061213100666000_53.6.592.28","doi-asserted-by":"crossref","first-page":"R71","DOI":"10.1186\/ar1454","article-title":"Elevated matrix metalloproteinase-9 in patients with systemic sclerosis","volume":"7","author":"Kim","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"2026061213100666000_53.6.592.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201910-1977OC"},{"key":"2026061213100666000_53.6.592.30","doi-asserted-by":"crossref","first-page":"101654","DOI":"10.1016\/j.jbc.2022.101654","article-title":"Engineering of tissue inhibitor of metalloproteinases TIMP-1 for fine discrimination between closely related stromelysins MMP-3 and MMP-10","volume":"298","author":"Raeeszadeh-Sarmazdeh","year":"2022","journal-title":"J Biol Chem"},{"key":"2026061213100666000_53.6.592.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201958"},{"key":"2026061213100666000_53.6.592.32","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-7-61"},{"key":"2026061213100666000_53.6.592.33","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2989"},{"key":"2026061213100666000_53.6.592.34","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/FJC.0000000000001268","article-title":"Dapagliflozin attenuates contrast-induced acute kidney injury by regulating the HIF-1\u03b1\/HE4\/NF-\u03baB pathway","volume":"79","author":"Huang","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026061213100666000_53.6.592.35","doi-asserted-by":"publisher","DOI":"10.1002\/path.4359"},{"key":"2026061213100666000_53.6.592.36","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/annrheumdis-2018-eular.4426","article-title":"FRI0473 Mpo-anca positivity is related to interstitial lung disease in systemic sclerosis","volume":"77","author":"Ichimura","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026061213100666000_53.6.592.37","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.3390\/jcm11133835","article-title":"Anti-inflammatory and\/or anti-fibrotic treatment of MPO-ANCA-positive interstitial lung disease: a short review","volume":"11","author":"Yamakawa","year":"2022","journal-title":"J Clin Med"},{"key":"2026061213100666000_53.6.592.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2009.02233.x"},{"key":"2026061213100666000_53.6.592.39","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1186\/s40064-016-3106-4","article-title":"Associations between peripheral blood eosinophil counts in patients with systemic sclerosis and disease severity","volume":"5","author":"Ando","year":"2016","journal-title":"Springerplus"},{"key":"2026061213100666000_53.6.592.40","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1007\/s10238-023-01125-x","article-title":"Type 2 cytokines and scleroderma interstitial lung disease","volume":"23","author":"Pellicano","year":"2023","journal-title":"Clin Exp Med"},{"key":"2026061213100666000_53.6.592.41","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2106012"},{"key":"2026061213100666000_53.6.592.42","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.4049\/jimmunol.156.3.1174","article-title":"Extracellular matrix proteins attenuate activation and degranulation of stimulated eosinophils","volume":"156","author":"Kita","year":"1996","journal-title":"J Immunol"},{"key":"2026061213100666000_53.6.592.43","doi-asserted-by":"crossref","first-page":"1015529","DOI":"10.3389\/fimmu.2022.1015529","article-title":"Regulation and directed inhibition of ECP production by human neutrophils","volume":"13","author":"Vega-Rioja","year":"2022","journal-title":"Front Immunol"},{"key":"2026061213100666000_53.6.592.44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M104871200"},{"key":"2026061213100666000_53.6.592.45","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12139"},{"key":"2026061213100666000_53.6.592.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.12.010"},{"key":"2026061213100666000_53.6.592.47","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2023-001803"},{"key":"2026061213100666000_53.6.592.48","doi-asserted-by":"publisher","DOI":"10.1007\/s13105-015-0389-9"},{"key":"2026061213100666000_53.6.592.49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41401-021-00666-9","article-title":"The adipokine orosomucoid alleviates adipose tissue fibrosis via the AMPK pathway","volume":"43","author":"Wang","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"2026061213100666000_53.6.592.50","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2613.2003.00336.x"},{"key":"2026061213100666000_53.6.592.51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41598-018-37406-9","article-title":"Relationships of haptoglobin phenotypes with systemic inflammation and the severity of chronic obstructive pulmonary disease","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"2026061213100666000_53.6.592.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2008.04.010"},{"key":"2026061213100666000_53.6.592.53","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.4049\/jimmunol.162.10.6226","article-title":"TNF-induced haptoglobin release from human neutrophils: pivotal role of the TNF p55 Receptor1","volume":"162","author":"Berkova","year":"1999","journal-title":"J Immunol"},{"key":"2026061213100666000_53.6.592.54","doi-asserted-by":"publisher","DOI":"10.1179\/135100001101536580"},{"key":"2026061213100666000_53.6.592.55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64759-x"},{"key":"2026061213100666000_53.6.592.56","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","article-title":"Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease","volume":"201","author":"Khanna","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061213100666000_53.6.592.57","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.3.1747-1754.2001"},{"key":"2026061213100666000_53.6.592.58","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jaci.2023.02.005","article-title":"Cystatin SN in type 2 inflammatory airway diseases","volume":"151","author":"Yan","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026061213100666000_53.6.592.59","doi-asserted-by":"crossref","first-page":"uxad077","DOI":"10.1093\/cei\/uxad077","article-title":"Senescence in diffuse systemic sclerosis is elevated and may play a role in fibrosis","volume":"219","author":"O\u2019Reilly","year":"2025","journal-title":"Clin Exp Immunol"},{"key":"2026061213100666000_53.6.592.60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fimmu.2012.00160","article-title":"The role of platelets in the pathogenesis of systemic sclerosis","volume":"3","author":"Ramirez","year":"2012","journal-title":"Front Immunol"},{"key":"2026061213100666000_53.6.592.61","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.96.2.382"},{"key":"2026061213100666000_53.6.592.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110189"},{"key":"2026061213100666000_53.6.592.63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114576"},{"key":"2026061213100666000_53.6.592.64","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2665-9913(24)00403-X","article-title":"Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study","volume":"7","author":"Hinchcliff","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"2026061213100666000_53.6.592.65","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2018-eular.3697","article-title":"OP0091 Cxcl10\/cxcl11 serum measurement as potential predictor of systemic sclerosis","volume":"77","author":"Antinozzi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026061213100666000_53.6.592.66","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.41627","article-title":"Predictive significance of serum interferon-inducible protein score for response to treatment in systemic sclerosis-related interstitial lung disease","volume":"73","author":"Assassi","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026061213100666000_53.6.592.67","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200409-1164OC"},{"key":"2026061213100666000_53.6.592.68","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.410720"},{"key":"2026061213100666000_53.6.592.69","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2007.1908"},{"key":"2026061213100666000_53.6.592.70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12967-021-02978-0","article-title":"GSTP1 as a novel target in radiation induced lung injury","volume":"19","author":"Lei","year":"2021","journal-title":"J Transl Med"},{"key":"2026061213100666000_53.6.592.71","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.4979"},{"key":"2026061213100666000_53.6.592.72","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3892\/ol.2012.1064","article-title":"Function and mode of action of cytohesins in the epidermal growth factor pathway in colorectal cancer cells","volume":"5","author":"Pan","year":"2013","journal-title":"Oncol Lett"},{"key":"2026061213100666000_53.6.592.73","doi-asserted-by":"crossref","first-page":"809896","DOI":"10.3389\/fimmu.2021.809896","article-title":"Cytohesin-2\/ARNO: A novel bridge between cell migration and immunoregulation in synovial fibroblasts","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"2026061213100666000_53.6.592.74","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3390\/jpm11050368","article-title":"S100A6, calumenin and cytohesin 2 as biomarkers for cutaneous involvement in systemic sclerosis patients: a case control study","volume":"11","author":"Balanescu","year":"2021","journal-title":"J Pers Med"},{"key":"2026061213100666000_53.6.592.75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041179"},{"key":"2026061213100666000_53.6.592.76","doi-asserted-by":"crossref","first-page":"jcs263638","DOI":"10.1242\/jcs.263638","article-title":"Mitochondrial topoisomerases, nucleoid architecture and mtDNA repair in human disease","volume":"138","author":"Bhattacharjee","year":"2025","journal-title":"J Cell Sci"},{"key":"2026061213100666000_53.6.592.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2014.01.009"},{"key":"2026061213100666000_53.6.592.78","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/art.41403","article-title":"Association of anti-topoisomerase I antibodies of the IgM isotype with disease progression in anti-topoisomerase I-positive systemic sclerosis","volume":"72","author":"Boonstra","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026061213100666000_53.6.592.79","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/23971983211064463","article-title":"Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography","volume":"7","author":"Khanna","year":"2022","journal-title":"J Scleroderma Relat Disord"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:11:03Z","timestamp":1781295063000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":79,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,1]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.3899\/jrheum.2025-0322"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0322","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]}}}